TRuE-V Data Suggest 2 Years Is the True Benchmark for Ruxolitinib Response

For clinicians managing vitiligo, one of the most challenging clinical conversations involves patients who see little to no skin improvement after months of treatment.¹ New 2-year data from the TRuE-V long-term extension study offer a compelling reason to counsel patience: the majority of patients on continuous ruxolitinib cream (Opzelura; Incyte) who showed minimal response at 6 months ultimately achieved meaningful repigmentation by the end of the second year.²

For decades, clinicians lacked an FDA-approved repigmentation therapy — a gap that changed in 2022 when ruxolitinib cream, a topical JAK1/JAK2 inhibitor, became the first treatment approved specifically for nonsegmental vitiligo in patients aged 12 and older.³ The approval was supported by the phase 3 TRuE-V1 and TRuE-V2 trials, which demonstrated significant repigmentation and favorable tolerability through 52 weeks. The TRuE-V long-term extension (LTE) subsequently documented continued improvement through 104 weeks. Despite these advances, a subset of patients show limited early response, raising practical questions about when — or whether — to continue therapy.

Study Design

The current analysis specifically examined patients from TRuE-V1 and TRuE-V2 who were initially randomized to twice-daily ruxolitinib cream 1.5% and who failed to achieve at least 25% improvement in either facial or total body repigmentation scores at week 24. Response was measured using the Facial Vitiligo Area Scoring Index (F-VASI) and Total Vitiligo Area Scoring Index (T-VASI). Eligible patients continued applying the cream twice daily and were followed through weeks 52, 80, and 104, with outcome data assessed at each interval. The analysis enrolled 127 patients with no or limited facial repigmentation and 193 with no or limited total body repigmentation at the 6-month mark.

Key Findings

The results challenge the notion of early non-response as a reliable predictor of long-term treatment failure. Among patients with no or limited facial repigmentation at week 24, the proportion showing any F-VASI improvement climbed from roughly 72% at week 52 to more than 90% by week 104. Notably, patients who had shown no facial repigmentation whatsoever at 6 months demonstrated a 97% response rate by 2 years.

The clinically meaningful threshold of 75% or greater improvement in F-VASI — considered a significant benchmark for facial repigmentation — was achieved by just 13% of this subgroup at week 52 but rose steadily to nearly 55% by week 104.

Similar trends held for total body repigmentation. Among patients with early limited body response, approximately 85% demonstrated T-VASI improvement at 2 years, and half achieved the T-VASI50 threshold — a 50% or greater reduction in total body disease burden — by the study's end.

Clinical Implications

These findings carry direct relevance for clinical practice. Vitiligo repigmentation is inherently slow, and patients — already prone to discouragement given the visible nature of the condition — may be inclined to discontinue therapy prematurely. The data suggest that a minimum of 24 months of continuous treatment may be necessary to capture the full therapeutic benefit in slower responders.

Clinicians should be aware of a key limitation: attrition bias may have shaped the results, as patients experiencing improvement would naturally be more likely to remain on treatment through the later time points. The numbers of patients with data available at weeks 80 and 104 were notably smaller than at week 52.

As the treatment landscape for vitiligo continues to evolve, these results reinforce that individualized shared decision-making — weighing the potential for late response against patient adherence, burden, and preferences — is essential. For patients who remain engaged with therapy, the 2-year horizon may be the more appropriate benchmark for assessing true treatment outcome.

References

1. Seneschal J, Boniface K. Vitiligo: Current therapies and future treatments. Dermatol Pract Concept. 2023;13(4S2):e2023313S. Published 2023 Dec 1. doi:10.5826/dpc.1304S2a313S
2. Wolkerstorfer A, Gooderham MJ, Sebastian M, et al. Prolonged ruxolitinib cream treatment for vitiligo among patients with no or limited response in the first 6 months. J Eur Acad Dermatol Venereol. Published online March 7, 2026. doi:10.1111/jdv.70402
3. Monteiro E Silva G, Mohamed A, Ferreira C, Torres T. Treatment of vitiligo with topical ruxolitinib: a narrative review. Drugs Context. 2025;14:2025-5-2. Published 2025 Sep 15. doi:10.7573/dic.2025-5-2